Policy / Pricing US launches probe of German ‘underpayment’ for medicines PharmaphorumA Section 301 probe by the US Trade Representative into Germany's medicine pricing and reimbursement policies raises the threat of punitive tariffs.Read full story pharminent June 19, 2026 (Last updated: June 22, 2026) Pharmaphorum A Section 301 probe by the US Trade Representative into Germany’s medicine pricing and reimbursement policies raises the threat of punitive tariffs. Read full story Post navigation Previous: Biogen to acquire RayThera for up to $1bnNext: Denali sells FDA voucher for $195M to support neurodegenerative pipeline Related Stories Policy / Pricing Mid-cap biotechs join Trump’s latest round of drug pricing deals pharminent September 1, 2026 Policy / Pricing MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones pharminent August 27, 2026 Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026